Organic redox additive incorporated PANI hydrogel electrodes for flexible high-energy-density supercapacitors

Dou, Liyang; Zhou, Shixiang; Ma, Jie; Zhao, Cheng; Cui, Peixin; Ye, Shifang; Feng, Peizhong; Gu, Xiuquan; Huang, Sheng; Tao, Xueyu

doi:10.1039/d3tc03119e

Cited by 5 publications

(1 citation statement)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite lacking the typical HRD genomic scarring, CDK12-altered tumors have a distinct tandem duplication signature and may be more susceptible to chemotherapy and PARPis than other HRP tumors (77). Aside from alterations in CCNE1, AKT2 and CDK12, the majority of HRP HGSC remain poorly defined, and integration of genomic, immune, proteomic and functional data is needed for their complete characterization (78)(79)(80)(81).…”

Section: Genomic Characteristicsmentioning

confidence: 99%

Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group

Stiegeler,

Garsed,

Au-Yeung

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Approximately 50% of tubo-ovarian high-grade serous carcinomas (HGSCs) have functional homologous recombination-mediated (HR) DNA repair, so-called HR-proficient tumors, which are often associated with primary platinum resistance (relapse within six months after completion of first-line therapy), minimal benefit from poly(ADP‐ribose) polymerase (PARP) inhibitors, and shorter survival. HR-proficient tumors comprise multiple molecular subtypes including cases with CCNE1 amplification, AKT2 amplification or CDK12 alteration, and are often characterized as “cold” tumors with fewer infiltrating lymphocytes and decreased expression of PD-1/PD-L1. Several new treatment approaches aim to manipulate these negative prognostic features and render HR-proficient tumors more susceptible to treatment. Alterations in multiple different molecules and pathways in the DNA damage response are driving new drug development to target HR-proficient cancer cells, such as inhibitors of the CDK or P13K/AKT pathways, as well as ATR inhibitors. Treatment combinations with chemotherapy or PARP inhibitors and agents targeting DNA replication stress have shown promising preclinical and clinical results. New approaches in immunotherapy are also being explored, including vaccines or antibody drug conjugates. Many approaches are still in the early stages of development and further clinical trials will determine their clinical relevance. There is a need to include HR-proficient tumors in ovarian cancer trials and to analyze them in a more targeted manner to provide further evidence for their specific therapy, as this will be crucial in improving the overall prognosis of HGSC and ovarian cancer in general.

show abstract

Section: Genomic Characteristicsmentioning

confidence: 99%

Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group

Stiegeler,

Garsed,

Au-Yeung

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Three-dimensional porous carbon-supported Co/Fe bimetallic nanoparticles derived from carboxymethyl cellulose for enhanced supercapacitor electrodes

Gao,

Zhao,

et al. 2024

Journal of Alloys and Compounds

View full text Add to dashboard Cite

Ag NPs-modified NiCoMn layered double hydroxides electrodes for high-performance asymmetric supercapacitors

Ali,

Marwat,

Khan

et al. 2024

Journal of Alloys and Compounds

View full text Add to dashboard Cite

Organic redox additive incorporated PANI hydrogel electrodes for flexible high-energy-density supercapacitors

Abstract: Organic redox additive hydroquinone (HQ) is incorporated into PANI hydrogel electrodes for flexible high-energy-density supercapacitors.

Cited by 5 publications

References 67 publications

Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group

Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group

Three-dimensional porous carbon-supported Co/Fe bimetallic nanoparticles derived from carboxymethyl cellulose for enhanced supercapacitor electrodes

Ag NPs-modified NiCoMn layered double hydroxides electrodes for high-performance asymmetric supercapacitors

Contact Info

Product

Resources

About